Elsevier

Ophthalmology

Volume 104, Issue 1, January 1997, Pages 137-142
Ophthalmology

A Comparison of Dorzolamide and Timolol in Patients with Pseudoexfoliation and Glaucoma or Ocular Hypertension

https://doi.org/10.1016/S0161-6420(97)30348-0Get rights and content

Purpose: The purpose of the study is to compare the efficacy and safety profile of 2.0% dorzolamide (three times daily) and 0.5% timolol (twice daily) for up to 6 months in patients with glaucoma or ocular hypertension associated with pseudoexfoliation. The additive effects of dorzolamide and timolol in patients requiring add-on therapy also was evaluated.

Methods: This was a double-masked, randomized, parallel comparison study at 15 Scandinavian sites. One hundred eighty-four patients with pseudoexfoliation and either glaucoma or ocular hypertension who were 21 to 85 years of age were studied. The treatment groups were 2.0% dorzolamide three times daily and 0.5% timolol maleate twice daily.

Results: At 6 months, the mean percent reduction in intraocular pressure of 2% dorzolamide and 0.5% timolol was 24% and 29%, respectively, at morning peak and 21% and 23%, respectively, at afternoon trough. The additional intraocular pressurelowering effect of adding 2.0% dorzolamide twice daily to patients receiving timolol was 14% and 15%, at peak and trough, respectively. There were no differences between treatment groups in the incidence of clinical adverse experiences, and dorzolamide was not associated with the systemic adverse effects typically ascribed to the use of oral carbonic anhydrase inhibitors.

Conclusion: Two percent dorzolamide (three times daily) was effective and well tolerated in patients with glaucoma or ocular hypertension associated with pseudoexfoliation over the course of 6 months; 0.5% timolol (twice daily) had a greater level of intraocular pressure-lowering activity than did dorzolamide, although the difference between the two treatments became less pronounced during the study period. Finally, 2.0% dorzolamide (twice daily) produced additional lowering of intraocular pressure when given with 0.5% timolol (twice daily).

References (34)

  • MF Sugrue et al.

    A comparison of L-671,152 and MK-927, two topically effective ocular hypotensive carbonic anhydrase inhibitors, in experimental animals

    Curr Eye Res

    (1990)
  • AM Bron et al.

    MK-927: a topically effective carbonic anhydrase inhibitor in patients

    Arch Ophthalmol

    (1989)
  • EJ Higginbotham et al.

    MK-927: a topical carbonic anhydrase inhibitor

    Dose response and duration of action. Arch Ophthalmol

    (1990)
  • EA Lippa et al.

    Multiple-dose, dose-response relationship for the topical carbonic anhydrase inhibitor MK-927

    Arch Ophthalmol

    (1991)
  • A Bron et al.

    Multiple-dose efficacy comparison of the two topical carbonic anhydrase inhibitors sezolamide and MK-927

    Arch Ophthalmol

    (1991)
  • A Tarkkanen

    Treatment of chronic open-angle glaucoma associated with pseudoexfoliation

    Acta Ophthalmol Scand

    (1965)
  • I Hrven

    Exfoliation syndrome: incidence and prognosis of glaucoma capsulare in Massachusetts

    Arch Ophthalmol

    (1966)
  • Cited by (0)

    **

    Dr. Strahlman and Mr. Tipping were employees of Merck & Co, Inc, the manufacturer of dorzolamide, at the time this study was conducted.

    ***

    Dr. Strahlman currently is the Vice President of Corporate Medical Affairs for Bausch & Lomb.

    View full text